uniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 164,429 Shares of Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 164,429 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the sale, the chief executive officer owned 558,810 shares of the company’s stock, valued at $24,766,459.20. This trade represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Price Performance

Shares of QURE stock opened at $46.29 on Monday. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The stock’s fifty day moving average price is $24.74 and its 200 day moving average price is $22.17. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -13.30 and a beta of 0.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. On average, research analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth approximately $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new stake in shares of uniQure in the 4th quarter worth about $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $48,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in uniQure in the 3rd quarter valued at approximately $50,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Chardan Capital boosted their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Barclays raised shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $25.00 to $65.00 in a research note on Thursday. Finally, Leerink Partners upped their price objective on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday. Twelve investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, uniQure has an average rating of “Moderate Buy” and a consensus price target of $58.92.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.